Peptide Inhibitors Target Alpha-Synuclein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective in inhibiting alpha-synuclein aggregation and the prion-like spread of its aggregates, which are key contributors to neurodegenerative diseases such as Parkinson's disease, with limited understanding of the structural properties of pathological seeds.
Innovation Solution
Development of structure-based peptide inhibitors that bind to specific residues of alpha-synuclein, specifically targeting the NACore segment to prevent fibril formation and seeding, using computational design and rational peptide sequences to 'cap' growing aggregates and disrupt further aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment is provided, but they are ineffective in inhibiting alpha-synuclein aggregation and prion-like spread
Solution Approach 1:
The patent introduces peptide inhibitors as intermediary molecules that bind to alpha-synuclein aggregates and block their ability to seed further aggregation. These peptides act as mediators between the therapeutic agent and the pathological protein, preventing the harmful prion-like spread while maintaining solubility and stability.
Solution Approach 2:
The invention extracts and targets the specific functional domain responsible for aggregation (the NACore segment) using specially designed peptide sequences. By taking out this critical aggregation-prone region as the target, the therapy can specifically inhibit aggregation without affecting other functions of the full-length protein.
2Object-affected harmful factors
If structure-based peptide inhibitors are designed to target NACore, then aggregation inhibition is achieved, but specificity and precision are required
Solution Approach 1:
The patent applies local quality by designing peptides with specific sequence features optimized for binding to the NACore region. The inhibitors contain precisely positioned amino acids that match the structural characteristics of the aggregation-prone segment, ensuring high specificity and effective inhibition of aggregation while maintaining solubility.
Solution Approach 2:
The invention utilizes parameter changes by modifying peptide sequences to optimize binding affinity, solubility, and stability. Computational design allows systematic variation of amino acid parameters to achieve the optimal balance between aggregation inhibition and prevention of peptide self-aggregation.
3Reliability
If peptide inhibitors are used to cap growing aggregates, then fibril formation is prevented, but the mechanism requires detailed structural understanding
Solution Approach 1:
The patent applies preliminary action by designing and pre-testing peptide inhibitors in vitro before in vivo application. The computational design and structural modeling are performed in advance to predict effective sequences, allowing optimization of inhibition mechanisms before clinical use and reducing the need for extensive trial-and-error in complex biological systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide inhibitors effectively inhibit alpha-synuclein fibril formation and seeding in various model systems, reducing cytotoxicity and the spread of aggregates, providing a potential therapeutic approach for neurodegenerative diseases like Parkinson's.
Implementation Method 1
peptide inhibitors that bind to specific residues of alpha-synuclein, specifically targeting the NACore segment
Data Source
AI summary
This invention relates to inhibitory peptides which bind to α-synuclein molecules and inhibit α-synuclein amyloidogenic aggregation, α-synuclein cytotoxicity, and spread of α-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by α-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.